The future of Alzheimer’s treatment may come from light, sound, and electric pulses, not pills

A flickering light and a rhythmic hum may do what decades of drug trials could not.

Scientists at MIT have spent nearly a decade refining a non-invasive therapy called GENUS (Gamma ENtrainment Using Sensory Stimulation), and the results are turning heads in neuroscience labs worldwide.

In a landmark 2022 clinical study published in PLOS One, patients with mild Alzheimer’s disease who sat in front of a device emitting coordinated 40 Hz flickering light and sound for one hour a day showed measurable slowing of brain shrinkage, improved memory recall, and stronger connectivity in key brain networks compared to a control group.

Then in 2025, a long-term follow-up study published in Alzheimer’s & Dementia tracked five patients who continued daily GENUS therapy for two full years.

Three of those five showed reduced levels of a toxic protein called phosphorylated tau (pTau217), a hallmark of Alzheimer’s progression, alongside better cognitive performance.

This is not a cure.

But for a disease that has defeated virtually every pharmaceutical attempt to slow it, two years of stabilization with a device that looks like a pair of light goggles is remarkable.

Why Alzheimer’s Has Been So Hard to Treat

To understand why this approach matters, it helps to understand the scale of what we’re dealing with.

More than 55 million people worldwide are currently living with Alzheimer’s disease or other dementias, according to the Alzheimer’s Disease International.

In the United States alone, 7.4 million Americans aged 65 and older have Alzheimer’s in 2026, with that number projected to nearly double by 2060.

A new case of dementia is diagnosed somewhere in the world every three seconds.

Despite billions of dollars spent on drug development, most clinical trials targeting Alzheimer’s have failed.

The drugs that did receive approval, such as lecanemab and donanemab, are expensive, require infusions, and come with potentially serious side effects including brain swelling and bleeding.

They are not options for most of the world.

That backdrop is exactly why scientists started thinking differently.

How the Study Was Conducted

The GENUS research began in mice.

MIT neuroscientist Li-Huei Tsai and her colleagues discovered that exposing mice with Alzheimer’s-like symptoms to light flickering at exactly 40 cycles per second, a frequency in the “gamma” range of brain waves, dramatically reduced the buildup of amyloid plaques and tau tangles, the toxic protein clusters that destroy neurons in Alzheimer’s disease.

The gamma frequency is not random.

Gamma brain waves (32 to 100 Hz) are the brain’s highest-frequency rhythms.

They are associated with attention, memory, and high-level cognition, and they are significantly weakened in people with Alzheimer’s.

The idea behind GENUS was elegantly simple: if you can nudge the brain to sync back to 40 Hz using light and sound from the outside, maybe you can restore some of that lost function and help the brain clean itself.

To test this in humans, the MIT team built a device, essentially a panel of LEDs and a speaker, that flickered and pulsed at precisely 40 Hz.

Participants sat in front of it for one hour each day.

In Phase 2A of the trial, 15 patients with mild Alzheimer’s took part.

Half used the real device.

Half used a control device emitting non-therapeutic stimulation.

Neither group could reliably tell which device they had been given.

Findings From the Study

The results surprised even the researchers.

After three months of daily stimulation, the group using the 40 Hz device showed four notable improvements compared to the control group:

Less ventricular dilation and hippocampal shrinkage — meaning the brain was losing volume more slowly than expected.

Stronger functional connectivity in the default mode network, the brain’s hub for memory and self-referential thinking.

Better performance on the face-name delayed recall test, a standard measure of memory that is often among the first abilities Alzheimer’s steals.

More regular daily activity rhythms, which is significant because disrupted sleep and circadian patterns are both a symptom and an accelerant of Alzheimer’s progression.

The two-year extension study, involving patients who continued therapy at home, found that daily one-hour sessions were safe, feasible, and well-tolerated.

In two of the five patients who donated plasma samples, tau protein levels were measurably reduced, a finding that points toward actual disease modification rather than symptom management.

A review published in March 2025 by the MIT Picower Institute noted that labs around the world, including teams in China, Harvard Medical School, and other independent institutions, have now replicated the core findings in both animals and humans.

The consistency of the evidence across so many independent studies is what is making the scientific community take this seriously.

But Here Is What Most People Get Wrong About This Therapy

When people first hear about treating Alzheimer’s with a flickering light, the reaction is often skepticism.

It sounds too simple.

It sounds like the kind of claim that belongs in a late-night infomercial, not a peer-reviewed neuroscience journal.

That instinct is understandable, but it misses the deeper biology.

The brain is fundamentally an electrical organ.

About 86 billion neurons communicate with each other using precisely timed electrical pulses.

When those pulses fall out of sync, which is exactly what happens in Alzheimer’s, the consequences cascade: memories fail, amyloid builds up, the brain loses its ability to clear waste, and cognitive function deteriorates.

The real insight of GENUS is not that light is magic.

It is that the brain can be re-entrained from the outside using sensory input, the way a metronome can bring a room of out-of-sync musicians back into rhythm.

And critically, once the brain is oscillating at 40 Hz again, something extraordinary happens.

Microglia, the brain’s immune cells, become more active.

They begin clearing amyloid and tau proteins from the spaces between neurons.

The glymphatic system, which is the brain’s waste disposal network, flushes more efficiently.

Cerebrospinal fluid flow improves.

The 2024 Nature study by Murdock et al. confirmed this mechanism directly, showing that multisensory 40 Hz stimulation increased the diameter of meningeal lymphatic vessels by 19%, boosted cerebrospinal fluid accumulation in the cortex by 34%, and increased the flow of amyloid out to cervical lymph nodes by 47%.

That is not a placebo effect.

That is measurable, mechanistic biology.

How This Research Applies to Real Life

Here is what makes this research genuinely exciting for the 55 million people and their families living with Alzheimer’s right now.

The therapy does not require a hospital.

It does not require an infusion, a surgery, or even a prescription.

In the MIT trials, participants used the device at home.

One hour a day, sitting in a chair.

That is a treatment model that could scale globally in a way that drug infusions never will.

It is also far more affordable in concept.

Companies like Cognito Therapeutics are already developing commercial versions of the device, with clinical trials actively enrolling in the United States.

MIT’s own HOPE Study, which is recruiting participants and tracking the therapy’s long-term effects through BrightFocus Foundation, is expected to provide the largest and most rigorous dataset yet.

Electric Pulses Are Also Entering the Picture

Light and sound are not the only tools being explored.

Transcranial Alternating Current Stimulation (tACS) delivers weak electrical currents through electrodes placed on the scalp at the same 40 Hz frequency.

A Harvard Medical School team showed in 2022 that tACS at 40 Hz significantly reduced amyloid burden in study participants, adding another non-invasive pathway toward the same goal.

Repetitive Transcranial Magnetic Stimulation (rTMS) uses magnetic fields to induce electrical currents in targeted brain regions, allowing researchers to essentially fire gamma oscillations directly into specific circuits.

Early results with rTMS in Alzheimer’s patients have shown improvements in memory and preserved grey matter volume.

A 2024 pilot study on rTMS found evidence of structural preservation in the brain after 24 weeks of treatment, a result that continues to generate follow-up research.

Each of these tools, flickering light, pulsed sound, electric current, magnetic stimulation, works on the same fundamental principle.

Restore the rhythm. Activate the cleanup. Slow the damage.

What Scientists Still Do Not Know

It is important to be honest about what remains unproven.

The existing human trials have been small.

Five patients in one follow-up study, fifteen in the Phase 2A trial.

These are the sample sizes of early science, promising but not yet definitive.

Researchers still do not fully understand every step in the biological chain connecting a flickering light to reduced amyloid plaques.

Which neuropeptides are involved? Which cell types are most critical? Why did the therapy appear to work better in women in the long-term follow-up?

These are open questions.

The MIT team is actively studying them.

And there is a real risk that larger, more rigorous trials will find effects smaller or less consistent than the early results suggest.

Science has been humbled by Alzheimer’s before.

But the difference now is that the mechanism has been observed, replicated, and confirmed across species and laboratories, from MIT to Harvard to independent teams in China.

That level of convergence is rare, and it is what makes scientists cautiously optimistic rather than merely hopeful.

The Bigger Picture

There is something poetic about the possibility that a disease defined by the brain losing its rhythm could be treated by giving it a rhythm back.

For decades, the search for an Alzheimer’s cure focused almost entirely on chemistry, trying to find a drug that could block or clear amyloid plaques.

Most of those efforts failed.

This new wave of research asks a different question: what if we can change the physics of the brain instead?

What if we can use the brain’s own electrical language to reactivate its self-cleaning systems?

We do not have a cure yet.

But we have something we have rarely had in Alzheimer’s research: a coherent mechanism, reproducible results, and a treatment that patients can actually use at home without side effects that are worse than the disease itself.

The next few years of large-scale trials will tell us how far this approach can go.

For the millions of families watching a loved one slowly disappear, that is worth paying attention to.

Sources and Further Reading